Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPG 7236

Next Previous
X
Search
Drug Profile

IPG 7236

Alternative Names: IPG-7236

Latest Information Update: 23 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanjing Amifei Biopharmaceutical Technology
  • Developer Immunophage Biotech; Nanjing Amifei Biopharmaceutical Technology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CCR8 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 Mar 2022 Immunophage Biotech plans a phase I trial in Atopic Dermatitis (PO, Tablet) (NCT05288543), in April 2022
  • 07 Dec 2021 IPG 7236 is available for licensing as of 07 Dec 2021. http://www.immunophage.com.cn/quanqiuhezuo.html
  • 15 Nov 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT05142592)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top